Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q9)Dec 31, 2022 | (Q6)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -33.41%17.31M | 3.02%36.2M | 26.63%26M | -66.40%35.14M | -45.66%20.53M | -36.41%12.65M | 12.77%104.6M | -1.10%76.38M | -23.51%37.79M | -10.22%19.9M |
| Operating income | -33.41%17.31M | 3.02%36.2M | 26.63%26M | -66.40%35.14M | -45.66%20.53M | -36.41%12.65M | 12.77%104.6M | -1.10%76.38M | -23.51%37.79M | -10.22%19.9M |
| Cost of sales | 28.03%-16.67M | -5.89%-35.22M | -16.09%-23.16M | 69.05%-33.26M | 52.42%-19.95M | 46.44%-11.99M | -17.19%-107.48M | -0.08%-76.41M | 12.27%-41.93M | -5.61%-22.38M |
| Operating expenses | 28.03%-16.67M | -5.89%-35.22M | -16.09%-23.16M | 69.05%-33.26M | 52.42%-19.95M | 46.44%-11.99M | -17.19%-107.48M | -0.08%-76.41M | 12.27%-41.93M | -5.61%-22.38M |
| Gross profit | -77.27%646K | -47.77%982K | 387.48%2.84M | 165.32%1.88M | 114.07%583K | 126.67%663K | -375.93%-2.88M | -103.74%-33K | -357.33%-4.14M | -357.08%-2.49M |
| Administrative expenses | 34.05%-2.53M | -23.60%-9.35M | -105.24%-3.84M | -30.47%-7.57M | 82.44%-1.87M | -2.71%-5.04M | 45.43%-5.8M | 10.15%-14.25M | 14.71%-10.64M | -197.94%-4.91M |
| Impairment and provision | ---- | -430.75%-3.55M | 97.79%-118K | 126.83%1.07M | ---5.35M | ---- | 65.46%-4M | ---- | ---- | ---- |
| -Other impairment is provision | ---- | -430.75%-3.55M | 97.79%-118K | 126.83%1.07M | ---5.35M | ---- | 65.46%-4M | ---- | ---- | ---- |
| Special items of operating profit | 834.13%23.68M | 155.72%6.74M | 74.48%-3.23M | -452.12%-12.1M | -183.50%-12.64M | -121.04%-5.2M | 102.95%3.44M | -49.22%5.39M | 137.52%15.14M | -130.05%-2.35M |
| Operating profit | 602.51%21.8M | 69.01%-5.18M | 77.49%-4.34M | -80.84%-16.71M | -5,575.28%-19.27M | 1.72%-9.58M | 52.54%-9.24M | -104.06%-8.89M | 107.83%352K | -236.39%-9.75M |
| Financing cost | 0.00%-360K | 0.00%-720K | 0.00%-360K | 0.14%-720K | 50.07%-360K | 0.28%-360K | 1.64%-721K | 0.83%-1.08M | 0.96%-721K | 0.82%-361K |
| Earning before tax | 556.34%21.44M | 66.16%-5.9M | 76.07%-4.7M | -74.98%-17.43M | -5,220.60%-19.63M | 1.67%-9.94M | 50.70%-9.96M | -83.07%-9.97M | 92.93%-369K | -249.03%-10.11M |
| After-tax profit from continuing operations | 556.34%21.44M | 66.16%-5.9M | 76.07%-4.7M | -74.98%-17.43M | -5,220.60%-19.63M | 1.67%-9.94M | 50.55%-9.96M | -83.07%-9.97M | 92.93%-369K | -249.03%-10.11M |
| Earning after tax | 556.34%21.44M | 66.16%-5.9M | 76.07%-4.7M | -74.98%-17.43M | -5,220.60%-19.63M | 1.67%-9.94M | 50.55%-9.96M | -83.07%-9.97M | 92.93%-369K | -249.03%-10.11M |
| Profit attributable to shareholders | 556.34%21.44M | 66.16%-5.9M | 76.07%-4.7M | -74.98%-17.43M | -5,220.60%-19.63M | 1.67%-9.94M | 50.55%-9.96M | -83.07%-9.97M | 92.93%-369K | -249.03%-10.11M |
| Basic earnings per share | 555.13%0.071 | 66.26%-0.0195 | 76.00%-0.0156 | -75.15%-0.0578 | -5,316.67%-0.065 | 1.79%-0.0329 | 67.13%-0.033 | 33.60%-0.033 | 97.77%-0.0012 | -285.08%-0.0335 |
| Diluted earnings per share | 542.31%0.069 | 66.26%-0.0195 | 76.00%-0.0156 | -75.15%-0.0578 | -5,316.67%-0.065 | 1.79%-0.0329 | 67.13%-0.033 | 33.60%-0.033 | 97.77%-0.0012 | -287.15%-0.0335 |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | -- |
| Auditor | -- | Zhi Bao Xin Qin Certified Public Accountants Limited | -- | Zhi Bao Xin Qin Certified Public Accountants Limited | -- | -- | Kaiyuan Xinde Certified Public Accountants Co., Ltd. | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.